Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors

5Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background: Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on therapy. This article aims to explain this divergence in long term outcomes. Methods and results: By combining clinical and experimental observations with mathematical formulas we estimate that, in advanced GIST, the genetic changes responsible for resistance are generally already present at disease detection. Conclusion: This result has relevant clinical implications by providing support for the exploration of combination therapies.

Cite

CITATION STYLE

APA

Tomasetti, C., Demetri, G. D., & Parmigiani, G. (2013). Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors. F1000Research, 2. https://doi.org/10.12688/f1000research.2-152.v1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free